Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.

Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Objective The question of sustained remission in SLE has been highlighted recently following data published on the use of chimeric antigen receptor-T cell therapy in SLE. With the review, we wanted to ...

Background Neutrophil extracellular traps (NETs) are auto-antigenic DNA strands and potentially give rise to SLE-specific autoantibodies that can deposit in glomeruli. It has been shown that ...

Objectives Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Significant morbidity and early mortality necessitate early intervention. This study harnessed SLE-associated immune ...

Objective To investigate the clinical features and treatment outcomes of anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis in patients with SLE. Methods Between October 2014 and April ...

Background Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by systemic disease flares, renal complications, photosensitivity, and other clinical manifestations. A research ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Janus kinase (JAK) inhibitors have enriched our armamentarium to treat autoimmune rheumatic diseases, with their approval in inflammatory arthritides (rheumatoid arthritis, spondyloarthritides). The ...

Background Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). In Part A of the Phase 2 LILAC study ...

Purpose Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) can have many underlying causes, including inflammation (inflammatory NPSLE). Inflammatory NPSLE is rare and ...